News Daily News Sequencing HF Meds? Most Doctors Stick to Old Habits, Survey Says Todd Neale December 08, 2022
News Conference News AHA 2022 Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION Michael O'Riordan November 09, 2022
News Conference News AHA 2022 STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends Todd Neale November 07, 2022
News Conference News AHA 2022 TRANSFORM-HF: Torsemide No Better Than Furosemide for Hospitalized HF Todd Neale November 05, 2022
News Conference News HFSA 2022 GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions Michael O'Riordan October 04, 2022
News Conference News HFSA 2022 Dapagliflozin’s Benefits Similar in HF Patients With Improved EF: DELIVER Todd Neale October 04, 2022
News Conference News TCT 2022 HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza Todd Neale September 16, 2022
News Conference News ESC 2022 ARBs Halve Rate of Aortic Root Enlargement in Marfan: Meta-analysis Shelley Wood August 29, 2022
News Daily News Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds Shelley Wood July 25, 2022
News Daily News LVEF Analysis Digs Anew Into Revascularization Benefits in Ischemic CAD Michael O'Riordan July 11, 2022
News Daily News Quadruple Therapy Costs Prohibitive for Many HFrEF Patients L.A. McKeown June 21, 2022
News Conference News ESC Heart Failure 2022 HF Triple Therapy Doesn’t Seem Effective in True Preserved HF Shelley Wood May 25, 2022
News Conference News HRS 2022 Gains in HF Drug Therapy Raise Questions About ICD Benefit in Modern Era Todd Neale May 02, 2022
News Daily News Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries Todd Neale April 20, 2022
News Conference News ACC 2022 METEORIC-HF: Omecamtiv Mecarbil Doesn’t Boost Exercise Capacity in HFrEF Todd Neale April 08, 2022
News Conference News ACC 2022 PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization L.A. McKeown April 03, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Daily News A ‘Call to Action’ for HF Trials: More Black, Hispanic Patients Caitlin E. Cox March 31, 2022